,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-10-03 05:19:00,"Chicago, IL - October 03, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog.",0.018062572926282883,0.008472573012113571,0.9734649062156677,neutral,0.009589999914169312
1,2017-10-03 05:19:00,Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.,0.021041298285126686,0.011407552286982536,0.9675511121749878,neutral,0.00963374599814415
2,2017-10-03 05:19:00,"Stocks recently featured in the blog include Procter & Gamble (NYSE: PG- Free Report ), PetroChina (NYSE: PTR- Free Report ), Biogen (Nasdaq: BIIB- Free Report ), Accenture (NYSE: ACN- Free Report ) and Norfolk Southern (NYSE: NSC- Free Report ).",0.019196392968297005,0.010672626085579395,0.970130980014801,neutral,0.00852376688271761
3,2017-10-03 05:19:00,"Today, Zacks is promoting its ''Buy'' stock recommendations.",0.3684377670288086,0.010614300146698952,0.6209479570388794,neutral,0.3578234612941742
4,2017-10-03 05:19:00,Get #1Stock of the Day pick for free.,0.0864095613360405,0.03249066323041916,0.8810997605323792,neutral,0.05391889810562134
5,2017-10-03 05:19:00,"Here are highlights from Monday's Analyst Blog:

The Zacks Research Daily presents the best research output of our analyst team.",0.24418438971042633,0.009908846579492092,0.7459067702293396,neutral,0.23427554965019226
6,2017-10-03 05:19:00,"Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (NYSE: PG- Free Report ), PetroChina (NYSE: PTR- Free Report ) and Biogen (Nasdaq: BIIB- Free Report ).",0.048194341361522675,0.007503601256757975,0.9443020224571228,neutral,0.04069073870778084
7,2017-10-03 05:19:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
8,2017-10-03 05:19:00,"You can see all of today's research reports here >>>

Buy-rated Procter & Gamble 's estimates are trending upward over the last 60 days, hinting analysts' optimism about the company.",0.892289400100708,0.027988867834210396,0.07972174137830734,positive,0.864300549030304
9,2017-10-03 05:19:00,"P&G is known for its strong brand recognition, diversified portfolio, impressive product development capabilities and marketing prowess, as well as strong cash flow productivity.",0.8819406628608704,0.012043415568768978,0.1060158982872963,positive,0.8698972463607788
10,2017-10-03 05:19:00,The company is investing in its brands and products as well as redesigning the supply chain to improve productivity and organic growth.,0.8364386558532715,0.0114588038995862,0.15210258960723877,positive,0.824979841709137
11,2017-10-03 05:19:00,Procter & Gamble is speeding up innovations and investments to counter the softening industry growth.,0.8044552803039551,0.01263556070625782,0.18290908634662628,positive,0.79181969165802
12,2017-10-03 05:19:00,Its productivity improvements and cost-saving efforts are also consistently helping to boost profit level.,0.9573743343353271,0.018996182829141617,0.023629505187273026,positive,0.9383781552314758
13,2017-10-03 05:19:00,"However, major foreign exchange headwind, weak volumes, divestitures and slowing market growth have been hurting sales.",0.021540287882089615,0.9665626883506775,0.011897004209458828,negative,-0.9450224041938782
14,2017-10-03 05:19:00,A soft consumer-spending environment in developed markets and uncertainties in emerging countries also add to the worries.,0.07459784299135208,0.6691628694534302,0.25623923540115356,negative,-0.5945650339126587
15,2017-10-03 05:19:00,Shares of Procter & Gamble have underperformed the Zacks Soap and Cleaning Materials industry so far this year (+8.2% vs. +18.1%).,0.1337699145078659,0.8448710441589355,0.0213590320199728,negative,-0.7111011147499084
16,2017-10-03 05:19:00,(You can read the full research report on Procter & Gamble here >>> ).,0.013788774609565735,0.010992237366735935,0.9752189517021179,neutral,0.0027965372428297997
17,2017-10-03 05:19:00,"ADRs of PetroChina have declined -12.6% over the last six months, underperforming the Zacks International Integrated Energy industry, which has gained +6.2% over the same period.",0.017762795090675354,0.9732865691184998,0.00895057711750269,negative,-0.9555237889289856
18,2017-10-03 05:19:00,"But with higher oil prices helping the state-run giant report a jump in first-half profits, the stock might return to favor.",0.9218412637710571,0.04045798256993294,0.037700772285461426,positive,0.8813832998275757
19,2017-10-03 05:19:00,The energy titan's biggest unit - exploration and production - swung to profitability as oil price soared 50%.,0.9511035680770874,0.022949932143092155,0.02594648487865925,positive,0.9281536340713501
20,2017-10-03 05:19:00,"PTR also experienced strong natural gas demand, while operational optimization helped control costs.",0.9398742318153381,0.01718708500266075,0.04293862730264664,positive,0.9226871728897095
21,2017-10-03 05:19:00,"However, the analyst is concerned over China's decision to cut natural gas prices for industrial users that reduced margins in PTR's gas-wholesale business.",0.021235385909676552,0.9644758701324463,0.014288720674812794,negative,-0.9432404637336731
22,2017-10-03 05:19:00,A limited international operation and an ambitious investment program give investors more reason to be cautious on the stock.,0.669023871421814,0.03608423098921776,0.2948918640613556,positive,0.6329396367073059
23,2017-10-03 05:19:00,"Hence, while being incrementally positive on PTR, the analyst expects the ADRs to remain soft.",0.7549442052841187,0.1201232299208641,0.12493257969617844,positive,0.6348209977149963
24,2017-10-03 05:19:00,(You can read the full research report on PetroChina here >>> ).,0.011692389845848083,0.012626883573830128,0.9756807088851929,neutral,-0.0009344937279820442
25,2017-10-03 05:19:00,Shares of Buy-rated Biogen have outperformed the Zacks Biomedicals/Genetics industry in the last six months (+14.8% vs. +13.3%).,0.6205541491508484,0.35691574215888977,0.022530121728777885,positive,0.2636384069919586
26,2017-10-03 05:19:00,"Biogen has a strong position in the MS market, backed by a wide range of products.",0.6449998617172241,0.009640670381486416,0.3453594744205475,positive,0.6353591680526733
27,2017-10-03 05:19:00,Newly launched Spinraza for spinal muscular atrophy is also off to a promising start.,0.8612034916877747,0.014339210465550423,0.12445732206106186,positive,0.8468642830848694
28,2017-10-03 05:19:00,Spinraza has witnessed faster-than-expected adoption in the U.S. and Biogen is ramping up launch efforts outside the U.S.,0.8792513012886047,0.012840650975704193,0.10790801048278809,positive,0.8664106726646423
29,2017-10-03 05:19:00,The Zacks analyst is also encouraged by Biogen's efforts to diversify beyond MS to other areas like Alzheimer's.,0.9134093523025513,0.012965856119990349,0.07362479716539383,positive,0.9004434943199158
30,2017-10-03 05:19:00,"The company also spun off its hemophilia business in Feb 2017, which allows it to focus on neurology, its key area of expertise.",0.095277801156044,0.07772102952003479,0.8270012140274048,neutral,0.017556771636009216
31,2017-10-03 05:19:00,Estimates have moved up ahead of the Q3 earnings results.,0.6949015259742737,0.04632274806499481,0.2587757706642151,positive,0.6485787630081177
32,2017-10-03 05:19:00,The company has a positive record of earnings surprises in recent quarters.,0.9442597031593323,0.02228577248752117,0.03345456346869469,positive,0.9219739437103271
33,2017-10-03 05:19:00,"However, Biogen has its own set of challenges.",0.01796545274555683,0.01838168501853943,0.9636529088020325,neutral,-0.00041623227298259735
34,2017-10-03 05:19:00,"Despite its position in the MS market, the emergence of new PML cases for Tecfidera are likely to weigh heavily on the stock along with pipeline setbacks.",0.0884091705083847,0.8572754859924316,0.05431527644395828,negative,-0.7688663005828857
35,2017-10-03 05:19:00,"Meanwhile, the recent Ocrevus launch by Roche may create pressure on Tysabri's sales.",0.02309536561369896,0.9486743211746216,0.028230266645550728,negative,-0.9255789518356323
36,2017-10-03 05:19:00,(You can read the full research report on Biogen here >>> ).,0.013879170641303062,0.012286399491131306,0.9738344550132751,neutral,0.0015927711501717567
37,2017-10-03 05:19:00,Other noteworthy reports we are featuring today include Accenture (NYSE: ACN- Free Report ) and Norfolk Southern (NYSE: NSC- Free Report ).,0.030283544212579727,0.005926903337240219,0.9637895226478577,neutral,0.024356640875339508
38,2017-10-03 05:19:00,"It's hard to believe, even for us at Zacks.",0.08736173063516617,0.254048228263855,0.6585900187492371,neutral,-0.1666865050792694
39,2017-10-03 05:19:00,"But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.",0.8417097330093384,0.03877422213554382,0.11951606720685959,positive,0.8029354810714722
40,2017-10-03 05:19:00,And this outperformance has not just been a recent phenomenon.,0.07535909861326218,0.015217346139252186,0.9094235301017761,neutral,0.060141753405332565
41,2017-10-03 05:19:00,Over the years it has been remarkably consistent.,0.6927107572555542,0.013971779495477676,0.29331743717193604,positive,0.6787389516830444
42,2017-10-03 05:19:00,"From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over.",0.754240095615387,0.14411918818950653,0.10164069384336472,positive,0.6101208925247192
43,2017-10-03 05:19:00,Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.,0.5744941830635071,0.01052891369909048,0.41497692465782166,positive,0.5639652609825134
44,2017-10-03 05:19:00,"Today, Zacks is promoting its ''Buy'' stock recommendations.",0.3684377670288086,0.010614300146698952,0.6209479570388794,neutral,0.3578234612941742
45,2017-10-03 05:19:00,Get #1 Stock of the Day pick for free .,0.2226315140724182,0.024793583899736404,0.7525749206542969,neutral,0.1978379338979721
46,2017-10-03 05:19:00,Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.,0.06386703997850418,0.004654404241591692,0.9314785599708557,neutral,0.059212636202573776
47,2017-10-03 05:19:00,"Continuous coverage is provided for a universe of 1,150 publicly traded stocks.",0.036364275962114334,0.004866600502282381,0.9587691426277161,neutral,0.03149767592549324
48,2017-10-03 05:19:00,Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance.,0.054108913987874985,0.005191051866859198,0.9407000541687012,neutral,0.04891786351799965
49,2017-10-03 05:19:00,Recommendations and target prices are six-month time horizons.,0.013092893175780773,0.007127966266125441,0.9797791242599487,neutral,0.0059649269096553326
50,2017-10-03 05:19:00,"Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar.",0.044983625411987305,0.5624399185180664,0.3925764560699463,negative,-0.5174562931060791
51,2017-10-03 05:19:00,They're virtually unknown to the general public.,0.035764459520578384,0.0785161554813385,0.885719358921051,neutral,-0.04275169596076012
52,2017-10-03 05:19:00,"Yet today's 220 Zacks Rank #1 ""Strong Buys"" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015.",0.6580293774604797,0.017276067286729813,0.32469451427459717,positive,0.6407533288002014
53,2017-10-03 05:19:00,Its average gain has been a stellar +26% per year.,0.8422174453735352,0.0191669799387455,0.13861553370952606,positive,0.8230504393577576
54,2017-10-03 05:19:00,See these high-potential stocks free >>.,0.12527841329574585,0.05778927728533745,0.8169323205947876,neutral,0.0674891322851181
55,2017-10-03 05:19:00,"Get the full Report on PG - FREE

Get the full Report on PTR - FREE

Get the full Report on BIIB - FREE

Get the full Report on ACN - FREE

Get the full Report on NSC - FREE

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.",0.013372085057199001,0.009672466665506363,0.9769554138183594,neutral,0.0036996183916926384
56,2017-10-03 05:19:00,Past performance is no guarantee of future results.,0.023727279156446457,0.008731111884117126,0.9675416350364685,neutral,0.01499616727232933
57,2017-10-03 05:19:00,Inherent in any investment is the potential for loss.,0.023265572264790535,0.09617827832698822,0.8805561661720276,neutral,-0.07291270792484283
58,2017-10-03 05:19:00,"This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security.",0.011962415650486946,0.010706594213843346,0.9773310422897339,neutral,0.0012558214366436005
59,2017-10-03 05:19:00,No recommendation or advice is being given as to whether any investment is suitable for a particular investor.,0.01822577603161335,0.008984367363154888,0.9727898240089417,neutral,0.009241408668458462
60,2017-10-03 05:19:00,"It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable.",0.020858757197856903,0.007662615738809109,0.9714785814285278,neutral,0.013196141459047794
61,2017-10-03 05:19:00,All information is current as of the date of herein and is subject to change without notice.,0.01124907098710537,0.013303965330123901,0.9754469990730286,neutral,-0.002054894343018532
62,2017-10-03 05:19:00,Any views or opinions expressed may not reflect those of the firm as a whole.,0.008276145905256271,0.021656149998307228,0.9700676798820496,neutral,-0.013380004093050957
63,2017-10-03 05:19:00,"Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities.",0.009504852816462517,0.012596068903803825,0.9778990745544434,neutral,-0.0030912160873413086
64,2017-10-03 05:19:00,These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs.,0.14585068821907043,0.02033580094575882,0.8338135480880737,neutral,0.1255148947238922
65,2017-10-03 05:19:00,These are not the returns of actual portfolios of stocks.,0.010538044385612011,0.012450686655938625,0.9770112633705139,neutral,-0.0019126422703266144
66,2017-10-03 05:19:00,The S&P 500 is an unmanaged index.,0.022511588409543037,0.0801919475197792,0.8972964882850647,neutral,-0.05768036097288132
67,2017-10-03 05:19:00,Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.,0.01078665629029274,0.015373211354017258,0.9738401174545288,neutral,-0.004586555063724518
68,2017-10-03 05:19:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
69,2017-10-03 05:19:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
70,2017-10-03 05:19:00,"Click to get this free report

To read this article on Zacks.com click here.",0.02068457007408142,0.033159855753183365,0.9461556077003479,neutral,-0.012475285679101944
71,2017-10-03 05:19:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
